Intrauterine Device – Levo­nor­gestrel 52 mg [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2021-07-02 17:18 (117 d 21:17 ago) – Posting: # 22454
Views: 409

Hi Marianna,

» We used data from the article: "Comparative pharmacokinetic analysis of levonorgestrel-releasing intrauterine systems and » levonorgestrel-containing contraceptives with oral or subdermal administration route" Hofmann et. al, 2020.
» But the point still the number of subjects in this BE/BA study, because in this case, parallel design needs an intra+inter CV%.

Actually you need CVtotal. That’s not the sum (or average) of both. You need to average the variances and back-convert them to a CV. In [image]:

pooling <- function(CV.inter, CV.intra) {
  CV2var <- function(CV)  return(log(CV^2 + 1))
  var2CV <- function(var) return(sqrt(exp(var) - 1))
  return(var2CV(mean(c(CV2var(CV.inter), CV2var(CV.intra)))))
CV.inter <- 0.80
CV.intra <- 0.40 <- pooling(CV.inter, CV.intra)
cat("CV.inter =", sprintf("%.2f%%", 100 * CV.inter),
    "\nCV.inter =", sprintf("%.2f%%", 100 * CV.intra),
    "\ =", sprintf("%.2f%%", 100 *, "\n")


CV.inter = 80.00%
CV.inter = 40.00% = 61.59%

» But in a scientific literature review, we don't find something like that.

I don’t have this article. If the study was performed in a parallel design, you have already CVtotal. If it was not reported, you can calculate it from the confidence interval and the sample size by the function CVfromCI() in PowerTOST. If it was a crossover (very, very unlikely), use the code above.

» A suggestion about mitigating the error in subject number determination?

Not sure what you mean by that. Perhaps this article helps.

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,760 posts in 4,550 threads, 1,547 registered users;
online 10 (1 registered, 9 guests [including 2 identified bots]).
Forum time: Thursday 14:36 CEST (Europe/Vienna)

Always remember that you are absolutely unique.
Just like everyone else.    Margaret Mead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz